Natalia A. Koziolova
Research Subjects
Natalia A. Koziolova has a total of 486 co-authors. Here are the top co-authors by number of shared publications:
- Albert S. Galyavich
Kazan State Medical University
24 shared publications - Anna I. Chernyavina
Perm State Medical University named after Academician E.A. Wagner
20 shared publications - Gregory Pavlovich Arutyunov
Pirogov Russian National Research Medical University
20 shared publications - Ekaterina Iosifovna Tarlovskaya
Association "Eurasian Association of Therapists"; Privolzhsky Research Medical University
17 shared publications - Elena A. Polyanskaya
Ye.A. Vagner Perm State Medical University
16 shared publications - Iana Orlova
Lomonosov Moscow State University
16 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (7) , 7065
Role of Steroidal Mineralocorticoid Receptor Antagonists in the Treatment of Patients with Heart Failure with a Left Ventricular Ejection Fraction ≤40%. Expert council resolution
Mineralocorticoid receptor antagonists are currently considered as a standard therapy for patients with heart failure with a reduced left ventricular ejection fraction. This drug group includes agents with different efficacy and safety profiles. The expert council’s resolution addresses the differentiated use of mineralocorticoid receptor antagonists in the treatment of patients with heart failure with a left ventricular ejection fraction ≤40%.
- 1 September 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (7) , 7065
Open AccessRole of Steroidal Mineralocorticoid Receptor Antagonists in the Treatment of Patients with Heart Failure with a Left Ventricular Ejection Fraction ≤40%. Expert council resolution
Mineralocorticoid receptor antagonists are currently considered as a standard therapy for patients with heart failure with a reduced left ventricular ejection fraction. This drug group includes agents with different efficacy and safety profiles. The expert council’s resolution addresses the differentiated use of mineralocorticoid receptor antagonists in the treatment of patients with heart failure with a left ventricular ejection fraction ≤40%.
- 14 May 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (2)
Effect of atrial fibrillation paroxysm during ST-segment elevation myocardial infarction on the prognosis of patients under long-term follow-up
Objective. To evaluate the impact of paroxysmal atrial fibrillation (AF) during the development of ST segment elevation myocardial infarction (MI) on the prognosis of patients during long-term follow-up. Materials and methods. The study presents the results of the second stage (outpatient) of a prospective, two-stage, open-label, observational clinical trial. To assess the contribution of AF to the unfavorable prognosis of patients with ST-segment elevation MI, patients were divided into two groups. The first group included 42 patients (36.8 %) with ST-segment elevation MI without AF during hospitalization and in their medical history; the second group included 72 patients (63.2 %) with ST-segment elevation MI and paroxysmal AF during the index hospitalization for MI. To register an unfavorable prognosis, primary endpoints were determined - cardiovascular death associated with the development of recurrent MI, acute decompensation of chronic heart failure (ADHF), acute cerebrovascular accident (ischemic, hemorrhagic strokes, intracerebral hemorrhage, acute brain circulation disorders), as well as secondary endpoints: fatal recurrent MI, ADHF, stroke. Results. The follow-up duration was 22.2 ± 4.5 months from the first day of the index hospitalization with ST-segment elevation MI. During the follow-up, permanent AF was registered in 12 (16.7 %) patients of the second group, persistent/paroxysmal AF was registered in 35 (48.6 %), and recurrent paroxysms were not registered in 25 (49.0 %) of 51 patients with newly diagnosed AF during ST-segment elevation MI. In the first group, AF was newly diagnosed in 4 (9.5 %) patients during the follow-up. During 2 years of follow-up, the incidence of the primary endpoint was statistically significantly higher in the group of patients with AF (p = 0.004), as were the number of patients with a fatal outcome (p = 0.004) and the incidence of fatal stroke (p = 0.020). In case of paroxysmal AF development in patients with ST-segment elevation MI during index hospitalization, the OR of fatal events during 2 years of observation increases by 3.877 times (95 % CI 1.508–10.195), RR – by 2.399 (95 % CI 1.285–4.941), the OR of the frequency of fatal events increases by 4.021 times (95 % CI 1.518–10.946), RR – by 2.553 times (95 % CI 1.305–5.569), the OR of cardiovascular death – by 4.334 times (95 % CI 1.095–19.951), RR – by 3.501 (95 % CI 1.077–14.636), the OR of fatal stroke – by 1.388 (95 %CI 1.367–1.442), RR – 1.328 (95 %CI 1.265–1.396). Univariate analysis showed that the development of paroxysmal AF during the index hospitalization with ST-segment elevation MI increased the Odds ratio of CV death developing during 2 years of follow-up by 3.637 times (95 % CI 1.071–12.351, p = 0.038). The incidence of fatal recurrent MI and ADHF did not differ between the groups. Conclusions. During a two-year follow-up, 48.6 % of patients who had a STEMI and an episode of AF died from cardiovascular causes, which is 2.5 times higher than among those without rhythm disturbances (19.0 %) (p = 0.004). The development of paroxysmal AF during the index hospitalization with ST-segment elevation MI increases the odds ratio for the development of cardiovascular death over 2 years of follow-up by 3.637 times. The main cause of death in patients who had a STEMI with an episode of AF was stroke, the OR of which increased by 1.388 times, and the RR of which increased by 1.328 times. The incidence and timing of fatal recurrent MI and ADHF were not associated with paroxysmal AF in patients with ST-segment elevation MI.
- 14 May 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (2)
Effect of atrial fibrillation paroxysm during ST-segment elevation myocardial infarction on the prognosis of patients under long-term follow-up
Objective. To evaluate the impact of paroxysmal atrial fibrillation (AF) during the development of ST segment elevation myocardial infarction (MI) on the prognosis of patients during long-term follow-up. Materials and methods. The study presents the results of the second stage (outpatient) of a prospective, two-stage, open-label, observational clinical trial. To assess the contribution of AF to the unfavorable prognosis of patients with ST-segment elevation MI, patients were divided into two groups. The first group included 42 patients (36.8 %) with ST-segment elevation MI without AF during hospitalization and in their medical history; the second group included 72 patients (63.2 %) with ST-segment elevation MI and paroxysmal AF during the index hospitalization for MI. To register an unfavorable prognosis, primary endpoints were determined - cardiovascular death associated with the development of recurrent MI, acute decompensation of chronic heart failure (ADHF), acute cerebrovascular accident (ischemic, hemorrhagic strokes, intracerebral hemorrhage, acute brain circulation disorders), as well as secondary endpoints: fatal recurrent MI, ADHF, stroke. Results. The follow-up duration was 22.2 ± 4.5 months from the first day of the index hospitalization with ST-segment elevation MI. During the follow-up, permanent AF was registered in 12 (16.7 %) patients of the second group, persistent/paroxysmal AF was registered in 35 (48.6 %), and recurrent paroxysms were not registered in 25 (49.0 %) of 51 patients with newly diagnosed AF during ST-segment elevation MI. In the first group, AF was newly diagnosed in 4 (9.5 %) patients during the follow-up. During 2 years of follow-up, the incidence of the primary endpoint was statistically significantly higher in the group of patients with AF (p = 0.004), as were the number of patients with a fatal outcome (p = 0.004) and the incidence of fatal stroke (p = 0.020). In case of paroxysmal AF development in patients with ST-segment elevation MI during index hospitalization, the OR of fatal events during 2 years of observation increases by 3.877 times (95 % CI 1.508–10.195), RR – by 2.399 (95 % CI 1.285–4.941), the OR of the frequency of fatal events increases by 4.021 times (95 % CI 1.518–10.946), RR – by 2.553 times (95 % CI 1.305–5.569), the OR of cardiovascular death – by 4.334 times (95 % CI 1.095–19.951), RR – by 3.501 (95 % CI 1.077–14.636), the OR of fatal stroke – by 1.388 (95 %CI 1.367–1.442), RR – 1.328 (95 %CI 1.265–1.396). Univariate analysis showed that the development of paroxysmal AF during the index hospitalization with ST-segment elevation MI increased the Odds ratio of CV death developing during 2 years of follow-up by 3.637 times (95 % CI 1.071–12.351, p = 0.038). The incidence of fatal recurrent MI and ADHF did not differ between the groups. Conclusions. During a two-year follow-up, 48.6 % of patients who had a STEMI and an episode of AF died from cardiovascular causes, which is 2.5 times higher than among those without rhythm disturbances (19.0 %) (p = 0.004). The development of paroxysmal AF during the index hospitalization with ST-segment elevation MI increases the odds ratio for the development of cardiovascular death over 2 years of follow-up by 3.637 times. The main cause of death in patients who had a STEMI with an episode of AF was stroke, the OR of which increased by 1.388 times, and the RR of which increased by 1.328 times. The incidence and timing of fatal recurrent MI and ADHF were not associated with paroxysmal AF in patients with ST-segment elevation MI.
- Open Access
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Open AccessRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- 16 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (3)
Prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%: value of the results of the FINEARTS-HF phase III randomized clinical trial (expert panel summary)
Heart failure with mildly reduced and preserved ejection fraction is a serious problem in modern healthcare due to its high prevalence, unfavorable prognosis, and significant limitations in optimal therapy. This article represents the resolution of an expert panel devoted to the prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%, based on the results of the FINEARTS-HF phase III randomized clinical trial. The data obtained demonstrate a high efficacy and safety profile for finerenone in this patient group, which rationales including this drug in widespread clinical practice for the treatment of symptomatic heart failure with a left ventricular ejection fraction ≥40% after registration of the appropriate indication.
- 16 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (3)
Prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%: value of the results of the FINEARTS-HF phase III randomized clinical trial (expert panel summary)
Heart failure with mildly reduced and preserved ejection fraction is a serious problem in modern healthcare due to its high prevalence, unfavorable prognosis, and significant limitations in optimal therapy. This article represents the resolution of an expert panel devoted to the prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%, based on the results of the FINEARTS-HF phase III randomized clinical trial. The data obtained demonstrate a high efficacy and safety profile for finerenone in this patient group, which rationales including this drug in widespread clinical practice for the treatment of symptomatic heart failure with a left ventricular ejection fraction ≥40% after registration of the appropriate indication.
- Open Access
- 3 March 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (1) , 21-34
Circadian blood pressure rhythm disturbances, pre-heart failure stage, and chronic kidney disease as predictors of adverse prognosis in patients with uncomplicated hypertension and long-term post-COVID syndrome
Objective. To identify predictors of poor prognosis in patients with arterial hypertension (AH) without associated clinical conditions who have long-term post-COVID syndrome (LPS). Materials and methods. This work presents a subanalysis of a prospective observational study, which included 258 patients with AH and LPS according to the inclusion and exclusion criteria. The incidence of fatal events and any hospitalizations was recorded throughout the follow-up period. At the end of the follow-up period, the patients were divided into 2 groups based on prognostic parameters: Group 1 included 65 patients who experienced adverse events, and Group 2 comprised 193 patients with no fatal events and hospitalizations during the observation period. Results. In 33.7 % of patients with uncomplicated AH, the development of LPS was associated with a risk of all-cause mortality (4.6 %) and hospitalizations (95.4 %) after 22.5 ± 8.4 months of follow-up. Uncontrolled AH based on home measurement, failure to achieve the target nocturnal blood pressure (BP), and a morning systolic BP surge 56 mm Hg increased the relative risk (RR) of an adverse prognosis in patients with AH, LPS, and no associated clinical conditions by 1.9-fold; a non-dipper/night-peaker circadian BP profile increased it by 3.2-fold; a mean 24-hour pulse pressure 53 mm Hg increased it by 2-fold; and nocturnal masked AH increased it by 3.6-fold. Structural and functional left ventricular (LV) remodeling characterized by LV diastolic dysfunction, LV hypertrophy, elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and indicative of preclinical chronic heart failure (CHF) in patients with uncomplicated AH and LPS without symptoms and signs of circulatory insufficiency, increased the RR of an adverse prognosis by an average of 2–2.5 times. Only an estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m2 (calculated using cystatin C alone or its combination with creatinine), and a urinary protein-to-creatinine ratio 300 mg/g, indicated a poor prognosis in patients with uncomplicated AH and LPS, increasing the RR by 2.0, 1.2, and 1.8 times, respectively. The development or progression of chronic kidney disease (CKD) in patients with AH and LPS increased the RR of poor prognosis by 2.2-fold. Conclusions. LPS in patients with uncomplicated AH is associated with a high incidence of adverse prognosis. The predictive value for adverse outcomes in this patient population was demonstrated by indicators reflecting the uncontrolled course of AH, particularly at night and early in the morning, the presence of preclinical CHF and CKD.
- 3 March 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (1) , 21-34
Open AccessCircadian blood pressure rhythm disturbances, pre-heart failure stage, and chronic kidney disease as predictors of adverse prognosis in patients with uncomplicated hypertension and long-term post-COVID syndrome
Objective. To identify predictors of poor prognosis in patients with arterial hypertension (AH) without associated clinical conditions who have long-term post-COVID syndrome (LPS). Materials and methods. This work presents a subanalysis of a prospective observational study, which included 258 patients with AH and LPS according to the inclusion and exclusion criteria. The incidence of fatal events and any hospitalizations was recorded throughout the follow-up period. At the end of the follow-up period, the patients were divided into 2 groups based on prognostic parameters: Group 1 included 65 patients who experienced adverse events, and Group 2 comprised 193 patients with no fatal events and hospitalizations during the observation period. Results. In 33.7 % of patients with uncomplicated AH, the development of LPS was associated with a risk of all-cause mortality (4.6 %) and hospitalizations (95.4 %) after 22.5 ± 8.4 months of follow-up. Uncontrolled AH based on home measurement, failure to achieve the target nocturnal blood pressure (BP), and a morning systolic BP surge 56 mm Hg increased the relative risk (RR) of an adverse prognosis in patients with AH, LPS, and no associated clinical conditions by 1.9-fold; a non-dipper/night-peaker circadian BP profile increased it by 3.2-fold; a mean 24-hour pulse pressure 53 mm Hg increased it by 2-fold; and nocturnal masked AH increased it by 3.6-fold. Structural and functional left ventricular (LV) remodeling characterized by LV diastolic dysfunction, LV hypertrophy, elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and indicative of preclinical chronic heart failure (CHF) in patients with uncomplicated AH and LPS without symptoms and signs of circulatory insufficiency, increased the RR of an adverse prognosis by an average of 2–2.5 times. Only an estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m2 (calculated using cystatin C alone or its combination with creatinine), and a urinary protein-to-creatinine ratio 300 mg/g, indicated a poor prognosis in patients with uncomplicated AH and LPS, increasing the RR by 2.0, 1.2, and 1.8 times, respectively. The development or progression of chronic kidney disease (CKD) in patients with AH and LPS increased the RR of poor prognosis by 2.2-fold. Conclusions. LPS in patients with uncomplicated AH is associated with a high incidence of adverse prognosis. The predictive value for adverse outcomes in this patient population was demonstrated by indicators reflecting the uncontrolled course of AH, particularly at night and early in the morning, the presence of preclinical CHF and CKD.
- Open Access
- 3 March 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (1) , 87-102
Predictors of atrial fibrillation in patients with ST-segment elevation myocardial infarction
Objective. To determine the predictors of atrial fibrillation (AF) development in patients with ST-segment elevation myocardial infarction (STEMI). Materials and methods. The study presents the results of the first (in-hospital) stage of a prospective, two-stage, open-label, observational clinical trial with a retrospective assessment of the patient data prior to their enrollment in the study. Over a 2-year period, 167 patients with STEMI were sequentially included into the study on admission to a multidisciplinary hospital according to the inclusion and exclusion criteria. To determine the predictors of AF development in STEMI patients, they were divided into 2 groups: Group 1 comprised 140 patients (83.8 %) with STEMI and no AF during hospitalization or in their medical history; Group 2 included 27 patients (16.2 %) with STEMI who experienced an AF paroxysm during hospitalization. Results. The prevalence of AF among 167 hospitalized patients with STEMI was 16.2 % (n=27). In 9.6 % of cases, AF paroxysm was verified for the first time, while in 6.8 % it was a manifestation of a pre-existing paroxysmal form. Systolic blood pressure BP 90 mmHg, heart rate 50 bpm and 110 bpm, and Killip class 1 increased the relative risk (RR) of AF paroxysm in MI patients by 2.3-fold, 6.1-fold, and 3.0-fold, respectively. Comorbid conditions such as obesity, chronic heart failure, and a history of pulmonary pathology increased the RR of AF by 2.6-fold, 2.3-fold, and 2.2-fold, respectively. Pre-admission use of renin-angiotensin-aldosterone system (RAAS) blockers and beta-blockers reduced the RR of AF development by 71 %, whereas the need for insulin therapy increased by 3.1-fold. In addition to the well-known predictors of AF development in MI associated with cardiac and renal remodeling, new ones were identified: left atrial contractile dysfunction index 40 %; left ventricular ejection fraction (LVEF)-to-indexed left atrial volume ratio 1.1; cystatin-based glomerular filtration rate 45 ml/min/1.73 m2; urinary albumin-to-creatinine ratio 300 mg/g; and creatinine-to-LVEF ratio. These increased the RR by 7.1-fold, 6.7-fold, 2.7-fold, 3.1-fold, and 2.7-fold, respectively. Among the new biomarkers associated with AF development in MI, the following were identified: blood apolipoprotein B100 (ApoB100) concentration 100 mg/dL; monocytes-to-high-density lipoprotein cholesterol ratio 26.5; tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) 124.2 ng/ml; platelet-to-lymphocyte ratio 212.1; inflammatory burden index 36.85; the combination of the GG genotype of the ApoB gene polymorphism Arg3500Gln (rs5742904) with the ID genotype of the fibrinogen alpha (FGA) gene polymorphism rs35496957. These increased the RR by 3.5-fold, 2.8-fold, 5.6-fold, 2.5-fold, 3.3-fold, and 3.6-fold, respectively. Conclusions. The study confirmed the clinical and historical predictors of AF paroxysm development in patients with STEMI and identified novel predictors associated with coupled structural and functional remodeling of the left and right ventricles, in combination with renal dysfunction, lipid metabolism disorders involving the apolipoprotein system, tissue fibrosis due to increased TIMP-1 levels, activation of nonspecific inflammation, anemia and pathological polymorphism of the ApoB100 and FGA genes.
- 3 March 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (1) , 87-102
Open AccessPredictors of atrial fibrillation in patients with ST-segment elevation myocardial infarction
Objective. To determine the predictors of atrial fibrillation (AF) development in patients with ST-segment elevation myocardial infarction (STEMI). Materials and methods. The study presents the results of the first (in-hospital) stage of a prospective, two-stage, open-label, observational clinical trial with a retrospective assessment of the patient data prior to their enrollment in the study. Over a 2-year period, 167 patients with STEMI were sequentially included into the study on admission to a multidisciplinary hospital according to the inclusion and exclusion criteria. To determine the predictors of AF development in STEMI patients, they were divided into 2 groups: Group 1 comprised 140 patients (83.8 %) with STEMI and no AF during hospitalization or in their medical history; Group 2 included 27 patients (16.2 %) with STEMI who experienced an AF paroxysm during hospitalization. Results. The prevalence of AF among 167 hospitalized patients with STEMI was 16.2 % (n=27). In 9.6 % of cases, AF paroxysm was verified for the first time, while in 6.8 % it was a manifestation of a pre-existing paroxysmal form. Systolic blood pressure BP 90 mmHg, heart rate 50 bpm and 110 bpm, and Killip class 1 increased the relative risk (RR) of AF paroxysm in MI patients by 2.3-fold, 6.1-fold, and 3.0-fold, respectively. Comorbid conditions such as obesity, chronic heart failure, and a history of pulmonary pathology increased the RR of AF by 2.6-fold, 2.3-fold, and 2.2-fold, respectively. Pre-admission use of renin-angiotensin-aldosterone system (RAAS) blockers and beta-blockers reduced the RR of AF development by 71 %, whereas the need for insulin therapy increased by 3.1-fold. In addition to the well-known predictors of AF development in MI associated with cardiac and renal remodeling, new ones were identified: left atrial contractile dysfunction index 40 %; left ventricular ejection fraction (LVEF)-to-indexed left atrial volume ratio 1.1; cystatin-based glomerular filtration rate 45 ml/min/1.73 m2; urinary albumin-to-creatinine ratio 300 mg/g; and creatinine-to-LVEF ratio. These increased the RR by 7.1-fold, 6.7-fold, 2.7-fold, 3.1-fold, and 2.7-fold, respectively. Among the new biomarkers associated with AF development in MI, the following were identified: blood apolipoprotein B100 (ApoB100) concentration 100 mg/dL; monocytes-to-high-density lipoprotein cholesterol ratio 26.5; tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) 124.2 ng/ml; platelet-to-lymphocyte ratio 212.1; inflammatory burden index 36.85; the combination of the GG genotype of the ApoB gene polymorphism Arg3500Gln (rs5742904) with the ID genotype of the fibrinogen alpha (FGA) gene polymorphism rs35496957. These increased the RR by 3.5-fold, 2.8-fold, 5.6-fold, 2.5-fold, 3.3-fold, and 3.6-fold, respectively. Conclusions. The study confirmed the clinical and historical predictors of AF paroxysm development in patients with STEMI and identified novel predictors associated with coupled structural and functional remodeling of the left and right ventricles, in combination with renal dysfunction, lipid metabolism disorders involving the apolipoprotein system, tissue fibrosis due to increased TIMP-1 levels, activation of nonspecific inflammation, anemia and pathological polymorphism of the ApoB100 and FGA genes.
- Open Access
- 15 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (1) , 6-27
Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists
More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.
- 15 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (1) , 6-27
Open AccessMenopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists
More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.
- 30 January 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 31 (5) , 446-458
Predictors of the development of cognitive impairment in hypertensive patients with long-term post-COVID syndrome
Objective. To determine the predictors of the development of cognitive impairment in patients with hypertension (HTN) with long-term post-COVID syndrome. Design and methods. A single-stage screening clinical study was conducted. Over a period of 3 years, 205 patients (23,4 %) with long-term post-COVID syndrome according to the NICE criteria were recruited among eligible 878 patients with HTN. The patients were divided taking into account the presence of cognitive impairment using the SEMOGRAPH information system: the first group included 80 patients (39,0 %) with cognitive impairment, the second group included 125 patients (61,0 %) without cognitive impairment. Results. The predictors of the development of cognitive impairment in patients with long-term post-COVID syndrome and their cut-off points were chosen using ROC curve: for body mass index values, a cut-off point of 28,36 kg/m 2 was set, > 26,0 mm/h — for erythrocyte sedimentation rate, < 126,0 g/l — for hemoglobin level, > 3,9 mg/l — for C-reactive protein serum concentration, > 101,9 pg/ml — for serum N-terminal fragment of brain natriuretic propeptide, > 171,1 μg/l — for ferritin, > 0,016 pg/ml — for serum tumor necrosis factor alpha, > 28,8 pg/ml — for serum caspase-6. In HTN patients with long-term post-COVID syndrome after hospitalization due to COVID-19-related pneumonia, the relative risk of cognitive impairment is increased by 2,8 times (95 % confidence interval (95 % CI) 1,63–4,92); the risk of concentration problems — by 8,1 times (95 % CI 4,84–13,99); “brain fog” symptom — by 2,5 times (95 % CI 1,75–3,50), abnormal blood pressure (BP) circadian profile “Non-dipper / Night-peaker systolic BP” — by 1,9 times (95 % CI 1,37–2,68); “Over-dipper systolic BP” — by 18,8 times (95 % CI 2,67–390,89); masked nocturnal hypertension — by 5,1 times (95 % CI 1,61–18,13). Conclusion. More severe forms of COVID-19, long-term post-COVID syndrome manifested by symptoms such as “brain fog”, impaired concentration, as well as abnormal patterns of circadian BP rhythm, obesity, ferrokinetic disorders, the development of myocardial stress, the presence of low-intensity non-specific inflammation, and signs of apoptosis were predictors of the development of cognitive impairment in COVID-19 survivors with HTN.
- 30 January 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 31 (5) , 446-458
Predictors of the development of cognitive impairment in hypertensive patients with long-term post-COVID syndrome
Objective. To determine the predictors of the development of cognitive impairment in patients with hypertension (HTN) with long-term post-COVID syndrome. Design and methods. A single-stage screening clinical study was conducted. Over a period of 3 years, 205 patients (23,4 %) with long-term post-COVID syndrome according to the NICE criteria were recruited among eligible 878 patients with HTN. The patients were divided taking into account the presence of cognitive impairment using the SEMOGRAPH information system: the first group included 80 patients (39,0 %) with cognitive impairment, the second group included 125 patients (61,0 %) without cognitive impairment. Results. The predictors of the development of cognitive impairment in patients with long-term post-COVID syndrome and their cut-off points were chosen using ROC curve: for body mass index values, a cut-off point of 28,36 kg/m 2 was set, > 26,0 mm/h — for erythrocyte sedimentation rate, < 126,0 g/l — for hemoglobin level, > 3,9 mg/l — for C-reactive protein serum concentration, > 101,9 pg/ml — for serum N-terminal fragment of brain natriuretic propeptide, > 171,1 μg/l — for ferritin, > 0,016 pg/ml — for serum tumor necrosis factor alpha, > 28,8 pg/ml — for serum caspase-6. In HTN patients with long-term post-COVID syndrome after hospitalization due to COVID-19-related pneumonia, the relative risk of cognitive impairment is increased by 2,8 times (95 % confidence interval (95 % CI) 1,63–4,92); the risk of concentration problems — by 8,1 times (95 % CI 4,84–13,99); “brain fog” symptom — by 2,5 times (95 % CI 1,75–3,50), abnormal blood pressure (BP) circadian profile “Non-dipper / Night-peaker systolic BP” — by 1,9 times (95 % CI 1,37–2,68); “Over-dipper systolic BP” — by 18,8 times (95 % CI 2,67–390,89); masked nocturnal hypertension — by 5,1 times (95 % CI 1,61–18,13). Conclusion. More severe forms of COVID-19, long-term post-COVID syndrome manifested by symptoms such as “brain fog”, impaired concentration, as well as abnormal patterns of circadian BP rhythm, obesity, ferrokinetic disorders, the development of myocardial stress, the presence of low-intensity non-specific inflammation, and signs of apoptosis were predictors of the development of cognitive impairment in COVID-19 survivors with HTN.
- 30 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11)
Mineralocorticoid receptor antagonists in internal medicine practice
Mineralocorticoid receptors (MRs) play a significant role in the pathogenesis of a number of internal diseases, including heart failure, hypertension, and chronic kidney disease. Their excessive activation contributes to the development of inflammation, fibrosis, tissue remodeling, and the development of cardiovacular-kidney-metabolic syndrome. The effectiveness of MR antagonism in promoting cardiac and renal protection has been confirmed by large experimental and clinical studies. However, there are significant differences in pharmacological properties between steroidal and nonsteroidal MR antagonists. This article presents the characteristics of MR antagonists registered in the Russian Federation, including their clinical effects, safety profile, and indications for use. Particular attention is paid to the drug selection algorithm, taking into account individual patient characteristics and the balance of potential benefits and risks. The material is based on current European and Russian clinical guidelines and is intended for practical use by internists in the management of patients with cardiovascular and renal diseases.
- 30 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11)
Mineralocorticoid receptor antagonists in internal medicine practice
Mineralocorticoid receptors (MRs) play a significant role in the pathogenesis of a number of internal diseases, including heart failure, hypertension, and chronic kidney disease. Their excessive activation contributes to the development of inflammation, fibrosis, tissue remodeling, and the development of cardiovacular-kidney-metabolic syndrome. The effectiveness of MR antagonism in promoting cardiac and renal protection has been confirmed by large experimental and clinical studies. However, there are significant differences in pharmacological properties between steroidal and nonsteroidal MR antagonists. This article presents the characteristics of MR antagonists registered in the Russian Federation, including their clinical effects, safety profile, and indications for use. Particular attention is paid to the drug selection algorithm, taking into account individual patient characteristics and the balance of potential benefits and risks. The material is based on current European and Russian clinical guidelines and is intended for practical use by internists in the management of patients with cardiovascular and renal diseases.
- Open Access
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 108-137
Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice.
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 108-137
Open AccessRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice.